BioScrip Inc. (NASDAQ:BIOS) traded down 3.3% during trading on Wednesday . The company traded as low as $2.62 and last traded at $2.63, with a volume of 303,504 shares changing hands. The stock had previously closed at $2.72.

Separately, Zacks Investment Research upgraded BioScrip from a “hold” rating to a “buy” rating and set a $3.00 price objective for the company in a research report on Monday, July 11th.

The stock’s 50 day moving average price is $2.59 and its 200-day moving average price is $2.30. The firm’s market capitalization is $182.27 million.

BioScrip (NASDAQ:BIOS) last posted its earnings results on Thursday, May 5th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by $0.05. The firm had revenue of $238.50 million for the quarter, compared to the consensus estimate of $232.38 million. The company’s revenue was down 2.4% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.17) EPS. Equities research analysts expect that BioScrip Inc. will post ($0.20) EPS for the current fiscal year.

In other news, Director Coliseum Capital Management, L bought 4,200,000 shares of the business’s stock in a transaction dated Wednesday, June 22nd. The stock was bought at an average price of $2.00 per share, for a total transaction of $8,400,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director David W. Golding bought 12,500 shares of the business’s stock in a transaction dated Friday, June 17th. The stock was purchased at an average price of $2.48 per share, with a total value of $31,000.00. Following the purchase, the director now directly owns 42,500 shares of the company’s stock, valued at approximately $105,400. The disclosure for this purchase can be found here.

An institutional investor recently raised its position in BioScrip stock. Diamond Hill Capital Management Inc. increased its position in shares of BioScrip Inc. (NASDAQ:BIOS) by 2.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,055,476 shares of the company’s stock after buying an additional 74,757 shares during the period. Diamond Hill Capital Management Inc. owned 4.44% of BioScrip worth $5,347,000 as of its most recent SEC filing.

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.